TheWealthWeb

Nippon India Nifty Pharma ETF

Nippon India Mutual FundOther Scheme - Other ETFsDirect · GrowthRisk: Very High

NAV ₹29.3403 on 13 November 2026

1 year
+26.24%
3 years, a year
+23.07%
5 years, a year
+16.26%
Since 18 Oct 2021, a year
+14.70%
NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY PHARMA TRI
1M+10.88%+9.46%
6M+16.12%+19.86%
1Y+26.24%+26.54%
3Y+23.07%+23.39%
5Y+16.26%+16.53%

Benchmark: NIFTY PHARMA TRI (total return index), measured over the same dates.

Risk

From daily NAVs. Alpha, beta and capture are measured against NIFTY PHARMA TRI.

Volatility
15.31%
Annualised, 3 years
Max drawdown
-16.55%
Worst fall from a peak, 3 years
Sharpe ratio
1.11
Return above the risk-free rate per unit of volatility, 3 years
Sortino ratio
1.60
Like Sharpe, counting only falls, 3 years
Alpha
-0.25%
Return a year beyond what beta explains, 3 years
Beta
1.00
1.00 moves in step with the benchmark, 3 years
Upside capture
99%
Share of the benchmark's rises captured, 3 years
Downside capture
100%
Share of the benchmark's falls taken (lower is better), 3 years

Every 3-year holding period

Worst
+13.99%
Median
+20.95%
Best
+26.54%
Ended positive
100.0%

Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.

Costs and fund facts

Expense ratio (stated maximum)
Direct 0.23% · Regular 0.00%
Exit load
Not Applicable
Fund size (all plans)
₹1,700 CrAverage, quarter to September 2026
Benchmark
NIFTY PHARMA TRI
Allotment date
2 July 2021Scheme document
Type
An open ended scheme replicating/ tracking NIFTY Pharma Index
AMFI scheme code
149008

Fund manager

  • Jitendra Tolanisince 01-Feb-2025

How each manager has done since taking over: fund manager scorecard.

Investment objective

The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 15 Nov 2021 to 13 Nov 2026
Total Invested61 mos
₹6,10,000
Units: 35,026.678
Current Portfolio Value
₹10,27,693
At latest recorded NAV
Total Profit
+₹4,17,693
+68.5% absolute return
SIP XIRR
21.01%
Annualised, money-weighted
Wealth CompositionProfit is 68% of total invested capital
Invested: ₹6,10,000Profit Generated: ₹4,17,693
Same SIP in the benchmark (NIFTY PHARMA TRI)Same dates & amounts
Scheme SIP Valuation
₹10,27,693
21.0% XIRR
Benchmark SIP Valuation
₹10,34,998
21.3% XIRR
Fund minus benchmark
₹-7,305
Over 61 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

Nippon India Nifty Pharma ETF is a mutual fund scheme from Nippon India Mutual Fund, listed by AMFI under “Other Scheme - Other ETFs”. Its NAV was ₹29.3403 on 13 November 2026. It returned 26.24% over 1 year, 23.07% a year over 3 years and 16.26% a year over 5 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY PHARMA TRI, returned 23.39% a year over 3 years. For an index fund or ETF, how closely it tracks its index matters more than its rank against other passive funds. The fund house rates its risk as “Very High” on the SEBI riskometer. Its average assets under management were ₹1,700 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 0.23% a year for the Direct plan. Managed by Jitendra Tolani. Its scheme summary document gives the allotment date as 2 July 2021.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns. Compare tracking difference across index funds.

Plans and options of this fund (1)

PlanOptionISINAMFI codeNAV
DirectThis pageGrowthINF204KC1089149008₹29.3413 Nov 2026